Published

Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Frontiers in psychiatry
Date: 2023-01-01
Source: PubMed
DOI: 10.3389/fpsyt.2023.1224551
PubMed: 37599880

Authors

Boehnke KF Cox K Weston C Herberholz M Glynos N Kolbman N Fields CW Barron J Kruger DJ

Watch author

Derived topics and classifications

psilocybin Observational Study Safety Adverse Events Drug Interactions Observational Study

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Safety and Mental Health Outcomes of Oregon State-Regulated Psilocybin ServicesJAMA Network Open · 2026-08-19 Real-world use, safety, and mental health efficacy of regulated psilocybin services in Oregon and ColoradomedRxiv · 2026-08-12 Psilocybin for Treatment-Resistant Depression in Autism: a Pilot Trial With Pre-Post Brain and Cognitive Measurement to Understand MechanismClinicalTrials.gov · 2026-08-06 An Exploratory Study of Feasibility, Efficacy, and Mechanisms of Mindfulness-Assisted Psychedelic TherapyClinicalTrials.gov · 2026-08-06 Evaluating psilocybin for the management of depression: a literature reviewBritish Journal of Mental Health Nursing · 2026-08-02 Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical TrialClinicalTrials.gov · 2026-07-28 PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical TrialClinicalTrials.gov · 2026-07-10 Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)ClinicalTrials.gov · 2026-07-09